201 related articles for article (PubMed ID: 11353615)
1. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
Delaney WE; Edwards R; Colledge D; Shaw T; Torresi J; Miller TG; Isom HC; Bock CT; Manns MP; Trautwein C; Locarnini S
Antimicrob Agents Chemother; 2001 Jun; 45(6):1705-13. PubMed ID: 11353615
[TBL] [Abstract][Full Text] [Related]
2. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
[TBL] [Abstract][Full Text] [Related]
3. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.
Delaney WE; Miller TG; Isom HC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2017-26. PubMed ID: 10428929
[TBL] [Abstract][Full Text] [Related]
4. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
León P; Pozo F; Echevarría JM
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.
Chin R; Shaw T; Torresi J; Sozzi V; Trautwein C; Bock T; Manns M; Isom H; Furman P; Locarnini S
Antimicrob Agents Chemother; 2001 Sep; 45(9):2495-501. PubMed ID: 11502520
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
Santos EA; Sucupira MV; Arabe J; Gomes SA
BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
8. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
[TBL] [Abstract][Full Text] [Related]
9. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
Delaney WE; Yang H; Westland CE; Das K; Arnold E; Gibbs CS; Miller MD; Xiong S
J Virol; 2003 Nov; 77(21):11833-41. PubMed ID: 14557667
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
11. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.
Ogata N; Fujii K; Takigawa S; Nomoto M; Ichida T; Asakura H
J Med Virol; 1999 Nov; 59(3):270-6. PubMed ID: 10502255
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.
Fu L; Liu SH; Cheng YC
Biochem Pharmacol; 1999 Jun; 57(12):1351-9. PubMed ID: 10353255
[TBL] [Abstract][Full Text] [Related]
13. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.
Fu L; Cheng YC
Antimicrob Agents Chemother; 2000 Dec; 44(12):3402-7. PubMed ID: 11083647
[TBL] [Abstract][Full Text] [Related]
14. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.
Pichoud C; Seignères B; Wang Z; Trépo C; Zoulim F
Hepatology; 1999 Jan; 29(1):230-7. PubMed ID: 9862871
[TBL] [Abstract][Full Text] [Related]
15. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus.
Shaw T; Locarnini SA
J Viral Hepat; 1999 Mar; 6(2):89-106. PubMed ID: 10607220
[TBL] [Abstract][Full Text] [Related]
16. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
Papatheodoridis GV; Dimou E; Papadimitropoulos V
Am J Gastroenterol; 2002 Jul; 97(7):1618-28. PubMed ID: 12135009
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant.
Tang S; Ho SK; Moniri K; Lai KN; Chan TM
Transplantation; 2002 Jan; 73(1):148-51. PubMed ID: 11792996
[TBL] [Abstract][Full Text] [Related]
18. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.
Heipertz RA; Miller TG; Kelley CM; Delaney WE; Locarnini SA; Isom HC
J Virol; 2007 Apr; 81(7):3068-76. PubMed ID: 17215289
[TBL] [Abstract][Full Text] [Related]
19. Perspectives for the treatment of hepatitis B virus infections.
De Clercq E
Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of three lamivudine-resistant HBV mutants with the method of restriction enzyme digestion and its application].
Sun J; Hou JL; Xiao L; Wang ZH; Zhang L; Luo KX
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Mar; 17(1):18-20. PubMed ID: 12870011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
